Renascience

Renascience Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Renascience (4889.T) as of Nov 19, 2026 is 1.01. In the previous year, Cash Conversion Cycle (CCC) was 389.98 — a change of -99.74% (lower).

Cash Conversion Cycle

1.01

YoY

-99.74%

Last updated:

Cash Conversion Cycle (CCC) of Renascience is 2026 1.01 . Cash Conversion Cycle (CCC) of Renascience was 2025 389.98 . It decreases by -99.74% lower compared to the previous year.

The Renascience Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2024
389.98 JPY
Jan 1, 2026
1.01 JPY
The Renascience Cash Conversion Cycle history
YEARCash Conversion CycleYoY
1.01-99.74%
389.98—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Cash Conversion Cycle (CCC) of Renascience is 1.01 in 2026.

Cash Conversion Cycle (CCC) of Renascience changed from 389.98 to 1.01, representing a -99.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Renascience since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Renascience with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Renascience

All Key Metrics — Renascience